High expression of ubiquitin carboxyl‑terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus‑associated liver cancer

  • Authors:
    • Yong Liao
    • Xingsi Liang
    • Wenjin Liang
    • Zeming Li
    • Yan Wang
    • Lin Wang
    • Siqi Zhen
    • Bo Tang
    • Zhenran Wang
  • View Affiliations

  • Published online on: March 15, 2019     https://doi.org/10.3892/ol.2019.10154
  • Pages: 5159-5168
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Deubiquitinating enzymes regulate protein activity and cell homeostasis by removing ubiquitin moieties from various substrates. Ubiquitin carboxyl‑terminal hydrolase 22 (USP22) is a member of the deubiquitinating protease family and is associated with the development of several tumor types. A previous study demonstrated that USP22 is highly expressed in liver cancer, and its high expression is associated with resistance to chemotherapy. However, the role of USP22 in hepatitis B virus (HBV)‑associated liver cancer has not yet been elucidated. The current study demonstrated that USP22 was highly expressed in the tissues of patients with HBV‑associated liver cancer, and its high expression was associated with clinicopathological characteristics, including tumor size, clinical stage and prognosis. Further results indicated that USP22 may regulate the proliferative and apoptotic abilities of HepG2.2.15 cells. Additionally, investigation into the underlying mechanism, using small interfering RNA, revealed that the downregulation of USP22 inhibited proliferation and promoted apoptosis though the phosphoinositide 3‑kinase/protein kinase B signaling pathway. Therefore, USP22 has the potential to be used as an independent predictor of patient prognosis, as well as a therapeutic target for the treatment of HBV‑associated liver cancer.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Bao J, Lu Y, Deng Y, Rong C, Liu Y, Huang X, Song L, Li S and Qin X: Association between IL-18 polymorphisms, serum levels, and HBV-related hepatocellular carcinoma in a Chinese population: A retrospective case-control study. Cancer Cell Int. 15:722015. View Article : Google Scholar : PubMed/NCBI

4 

Sun Y, Lu Y, Li T, Xie L, Deng Y, Li S and Qin X: Interferon gamma +874T/A polymorphism increases the risk of hepatitis virus-related diseases: Evidence from a meta-analysis. PLoS One. 10:e01211682015. View Article : Google Scholar : PubMed/NCBI

5 

Dastjerdi MN, Kavoosi F, Valiani A, Esfandiari E, Sanaei M, Sobhanian S, Hakemi MG and Mobarakian M: Inhibitory effect of genistein on PLC/PRF5 hepatocellular carcinoma cell line. Int J Prev Med. 6:542015. View Article : Google Scholar : PubMed/NCBI

6 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Peng Q, Yang S, Lao X, Li R, Chen Z, Wang J, Qin X and Li S: Association of single nucleotide polymorphisms in VDR and DBP genes with HBV-Related hepatocellular carcinoma risk in a chinese population. PLoS One. 9:e1160262014. View Article : Google Scholar : PubMed/NCBI

8 

Zhang T, Zhang J, You X, Liu Q, Du Y, Gao Y, Shan C, Kong G, Wang Y, Yang X, et al: Hepatitis B virus X protein modulates oncogene Yes-associated protein by CREB to promote growth of hepatoma cells. Hepatology. 56:2051–2059. 2012. View Article : Google Scholar : PubMed/NCBI

9 

Hodgson AJ, Hyser JM, Keasler VV, Cang Y and Slagle BL: Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology. 426:73–82. 2012. View Article : Google Scholar : PubMed/NCBI

10 

He P, Zhang D, Li H, Yang X, Li D, Zhai Y, Ma L and Feng G: Hepatitis B virus X protein modulates apoptosis in human renal proximal tubular epithelial cells by activating the JAK2/STAT3 signaling pathway. Int J Mol Med. 31:1017–1029. 2013. View Article : Google Scholar : PubMed/NCBI

11 

Arbuthnot P, Capovilla A and Kew M: Putative role of hepatitis B virus X protein in hepatocarcinogenesis: Effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways. J Gastroenterol Hepatol. 15:357–368. 2000. View Article : Google Scholar : PubMed/NCBI

12 

El-Serag HB: Hepatocellular carcinoma. N Engl J Med. 365:1118–1127. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Lin S, Hoffmann K and Schemmer P: Treatment of hepatocellular carcinoma: A systematic review. Liver Cancer. 1:144–158. 2012. View Article : Google Scholar : PubMed/NCBI

14 

Whittaker S, Marais R and Zhu AX: The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene. 29:4989–5005. 2010. View Article : Google Scholar : PubMed/NCBI

15 

Zhang XY, Pfeiffer HK, Thorne AW and McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell marker, reverses the polycomb-catalyzed ubiquitylation of histone H2A. Cell Cycle. 7:1522–1524. 2008. View Article : Google Scholar : PubMed/NCBI

16 

Lee HJ, Kim MS, Shin JM, Park TJ, Chung HM and Baek KH: The expression patterns of deubiquitinating enzymes, USP22 and Usp22. Gene Expr Patterns. 6:277–284. 2006. View Article : Google Scholar : PubMed/NCBI

17 

Piao S, Ma J, Wang W, Liu Y, Zhang M, Chen H and Guo F, Zhang B and Guo F: Increased expression of USP22 is associated with disease progression and patient prognosis of salivary duct carcinoma. Oral Oncol. 49:796–801. 2013. View Article : Google Scholar : PubMed/NCBI

18 

Li ZH, Yu Y, Du C, Fu H, Wang J and Tian YU: RNA interference-mediated USP22 gene silencing promotes human brain glioma apoptosis and induces cell cycle arrest. Oncol Lett. 5:1290–1294. 2013. View Article : Google Scholar : PubMed/NCBI

19 

Ning J, Zhang J, Liu W, Lang Y, Xue Y and Xu S: Overexpression of ubiquitin-specific protease 22 predicts poor survival in patients with early-stage non-small cell lung cancer. Eur J Histochem. 56:e462012. View Article : Google Scholar : PubMed/NCBI

20 

Piao S, Liu Y, Hu J, Guo F, Ma J, Sun Y and Zhang B: USP22 is m as a novel molecular Marker for predicting disease progression and patient prognosis of oral squamous cell carcinoma. PLoS One. 7:e425402012. View Article : Google Scholar : PubMed/NCBI

21 

Glinsky GV, Berezovska O and Glinskii AB: Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Bosman FT, Carneiro F, Hruban RH and Theise N: WHO Classification of tumours of the digestive system. 4th. IARC; Lyon: 2010

23 

Edge SB and Compton CC: The American Joint committee on cancer: The 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Hoeller D and Dikic I: Targeting the ubiquitin system in cancer therapy. Nature. 458:438–444. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Tang B, Tang F, Li B, Yuan S, Xu Q, Tomlinson S, Jin J, Hu W and He S: High USP22 expression indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 6:12654–12667. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Atanassov BS, Mohan RD, Lan X, Kuang X, Lu Y, Lin K, McIvor E, Li W, Zhang Y, Florens L, et al: ATXN7L3 and ENY2 coordinate activity of multiple H2B deubiquitinases important for cellular proliferation and tumor growth. Mol Cell. 62:558–571. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Tang B, Liang X, Tang F, Zhang J, Zeng S, Jin S, Zhou L, Kudo Y and Qi G: Expression of USP22 and Survivin is an indicator of malignant behavior in hepatocellular carcinoma. Int J Oncol. 47:2208–2216. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Zhang XY, Varthi M, Sykes SM, Phillips C, Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activator-driven transcription and cell cycle progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI

30 

Liu YL, Jiang SX, Yang YM, Xu H, Liu JL and Wang XS: USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem Biophys. 62:229–235. 2012. View Article : Google Scholar : PubMed/NCBI

31 

Atanassov BS and Dent SY: USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Ning Z, Wang A, Liang J, Xie Y, Liu J, Yan Q and Wang Z: USP22 promotes epithelial-mesenchymal transition via the FAK pathway in pancreatic cancer cells. Oncol Rep. 32:1451–1458. 2014. View Article : Google Scholar : PubMed/NCBI

33 

Hu J, Yang D, Zhang H, Liu W, Zhao Y, Lu H, Meng Q, Pang H, Chen X, Liu Y and Cai L: USP22 promotes tumor progression and induces epithelial-mesenchymal transition in lung adenocarcinoma. Lung Cancer. 88:239–245. 2015. View Article : Google Scholar : PubMed/NCBI

34 

Zhu M, Li W, Lu Y, Dong X, Lin B, Chen Y, Zhang X, Guo J and Li M: HBx drives alpha fetoprotein expression to promote initiation of liver cancer stem cells through activating PI3K/AKT signal pathway. Int J Cancer. 140:1346–1355. 2017. View Article : Google Scholar : PubMed/NCBI

35 

Liu H, Xu J, Zhou L, Yun X, Chen L, Wang S, Sun L, Wen Y and Gu J: Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway. Cancer Res. 71:7547–7557. 2011. View Article : Google Scholar : PubMed/NCBI

36 

Iyer SC, Gopal A and Halagowder D: Myricetin induces apoptosis by inhibiting P21 activated kinase 1 (PAK1) signaling cascade in hepatocellular carcinoma. Mol Cell Biochem. 407:223–237. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liao, Y., Liang, X., Liang, W., Li, Z., Wang, Y., Wang, L. ... Wang, Z. (2019). High expression of ubiquitin carboxyl‑terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus‑associated liver cancer. Oncology Letters, 17, 5159-5168. https://doi.org/10.3892/ol.2019.10154
MLA
Liao, Y., Liang, X., Liang, W., Li, Z., Wang, Y., Wang, L., Zhen, S., Tang, B., Wang, Z."High expression of ubiquitin carboxyl‑terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus‑associated liver cancer". Oncology Letters 17.6 (2019): 5159-5168.
Chicago
Liao, Y., Liang, X., Liang, W., Li, Z., Wang, Y., Wang, L., Zhen, S., Tang, B., Wang, Z."High expression of ubiquitin carboxyl‑terminal hydrolase 22 is associated with poor prognosis in hepatitis B virus‑associated liver cancer". Oncology Letters 17, no. 6 (2019): 5159-5168. https://doi.org/10.3892/ol.2019.10154